|
|
 |
| Scientific Program |
 |
|
|
Hall A |
|
|
|
|
08:30-10:00 |
Diabetes and Cancer
Chairs: S. Del Prato, Italy and I. Raz, Israel |
|
08:30-08:35 |
Introduction |
|
08:35-08:55
|
Pathogenesis of cancers in diabetes and obesity
D. Leroith, USA |
|
|
08:55-09:15
|
Insulin therapy and cancer
P. Home, UK |
|
09:15-09:35
|
Oral agents and cancer (metformin, sulfonylureas, thiazolidinediones)
R.A. DeFronzo, USA |
|
09:35-09:55
|
Newer therapies and cancer (incretin and SGLT2)
M. Nauck, Germany |
|
09:55-10:00 |
Discussion: Do we need malignancy outcome studies? |
|
10:0:00-10:30 |
Coffee Break |
|
|
10:30-12:00 |
Controversies in Diabetes Treatment
Chairs: P. Djordjevic, Serbia & B. Gallwitz, Germany |
|
10:30-10:35 |
Introduction |
|
|
10:35-10:50
10:50-11:05
11:05-11:20 |
How to start pharmacologic treatment?
Patho-physiological driven approach vs. Guideline approach
Patho-physiological driven approach: R.A. DeFronzo, USA
Guideline approach: I. Raz, Israel
Discussion |
|
|
11:20-11:35
11:35-11:50
|
How do we continue treatment of secondary failure?
Incretin vs. insulin treatment
Incretin: B. Gallwitz, USA
Insulin: R.G. Bretzel, Germany
Discussion |
|
|
13:00-15:00 |
Diabetes, Obesity and Hypertension
Chairs: A. Lejnieks, Latvia & E. Grossman, Israel |
|
13:00-13:05 |
Introduction |
|
|
13:05-13:20
|
Should we be targeting subclinical organ damage?
Yes: E. Grossman, Israel
No: G. Mancia, Italy |
|
|
13:35-13:50
13:50-14:05
14:05-14:20
14:20-14:35
|
Should our targets for control be different in the elderly?
Obesity
C. Tsigos, Greece
Blood pressure control
G. Grassi, Italy
Lipid control
R. Bitzur, Israel
Blood glucose control
Y. Kleinman, Israel
Discussion |
|
|
15:30-17:00 |
Diabetes and Related Disorders
Chair: P. Home, UK & S. Sadikot, India |
|
|
Introduction |
|
15:35-15:55
|
Sleep disorders
S. Sadikot, India |
|
15:55-16:15 |
Pancreatitis
G. Marchesini, Italy |
|
16:15-16:35
16:35-17:00 |
Diabetes, Dysglycemia and cognitive disfunction
T. Cukierman-Yaffee. Israel
Discussion |
|
Hall B |
|
|
|
|
10:30-12:00 |
News in Hypertension
Chairs: Y. Yodfat, Israel & G. Mancia, Italy |
|
10:30-10:35 |
Introduction |
|
|
10:35-10:55 |
Individualization of the management of hypertension
G. Mancia, Italy |
|
10:55-11:05
11:05-11:15
11:15-11:25 |
Blood pressure (BP) variability or average BP is the main determinant of future cardiovascular (CV) outcomes
Pro BP-variability: G. Parati, Italy
Pro-average BP: P. Nilsson, Sweden
Discussion |
|
|
11:25-11:35
11:35-11:45
11:45-12:00 |
Diagnosis of hypertension should be by ambulatory monitoring
Pro: E. Grossman, Israel
Con: P. Nilsson, Sweden
Discussion |
|
|
13:00-15:00 |
Obesity and Weight Loss
Chairs: D. Micic, Serbia & V. Hainer, Czech Republic |
|
13:00-13:05 |
Introduction |
|
|
13:05-13:20
13:20-13:35 |
Is obesity a brain disease?
Yes: N. Stern, Israel
No: N. Finer, UK |
|
13:35-13:50
13:50-14:05 |
Cardiovascular risk factor: The obesity paradox - Does it exist?
Against: E. Standl, Germany
In favor: V. Hainer, Czech Republic |
|
14:05-14:20
14:20-14:35
14:35-15:00 |
Physical exercise is a core element for every patient
Yes: P.P. De Feo, Italy
No: P. Schwarz, Germany
Discussion |
|
|
15:30-17:00 |
Bariatric Surgery
Chairs: J.C. Holm, Denmark & R. Taylor, UK |
|
15:30-15:35 |
Introduction |
|
15:35-15:50
15:50-16:05
16:05-16:15 |
Mechanism of metabolic advantage after bariatic surgery
It's all food restrictions: R. Taylor, UK
It's all gastro-intestinal factors: F.K. Knop, Denmark
Discussion |
|
16:15-16:30
16:30-16:45
16:45-17:00 |
Can surgery during adolescence be justified?
Yes: R. Weiss, Israel
No: J.C. Holm, Denmark
Discussion |
|
Hall C |
|
|
|
|
|
Unmet Needs in Obesity
Chairs: L. Van Gaal, Belgium & R. Weiss, Israel |
|
10:30-10:35 |
Introduction |
|
10:35-10:55 |
Obesity treatments: The state of the art
L. Van Gaal, Belgium |
|
10:55-11:15 |
Bariatric surgery in the prevention of type 2 diabetes: Long term experiences from the SOS study
L. Carlsson, Sweden |
|
11:15-11:35
11:35-12:00 |
From bariatric surgery to bariatric pill
G. Lieberman, Israel
Discussion |
|
|
13:00-15:00 |
The Kidney As a New Therapeutic Partner
Chair: G. Schernthaner, Austria & M. Puig Domingo, Spain
Supported by Janssen, Pharmaceutical Companies of Johnson & Johnson |
|
13:00-13:05 |
Introduction |
|
|
13:05-13:25 |
Hyperglycaemia, hypertension, obesity, and the kidney in people with T2D
L. Van Gaal, Belgium |
|
|
13:25-13:45 |
The kidney as a new therapeutic partner
J. Wilding, UK |
|
13:45-14:05 |
Clinical potential of SGLT-2 inhibition
J. Seufert, Germany |
|
14:05-14:25 |
How this new approach may help tackle clinical inertia
M. Puig Domingo, Spain |
|
14:25-15:00 |
Discussion |
|
|
15:30-17:00 |
Ongoing Discussions in Diabetes and Metabolic Syndrome
Chairs: J. Skrha, Czech Republic & A. Ceriello, Spain |
|
15:30-15:35 |
Introduction |
|
|
15:35-15:55
15:55-16:15 |
Postprandial hyperglycaemic variability: Should we care?
Yes: A. Ceriello, Spain
No: E.S. Kilpatrick, UK |
|
|
16:15-16:35
16:35-17:00 |
NAFLD/NASH- Is it an independent predictor of CV disease?
E. Bonora, Italy
Discussion |
|
|
17:00-19:00 |
Bristol-Myers Squibb / AstraZeneca Satellite Symposium |
|
|
|
|
WebStudio.co.il